Journal of Hebei Medical University ›› 2020, Vol. 41 ›› Issue (11): 1276-1280.doi: 10.3969/j.issn.1007-3205.2020.11.008

Previous Articles     Next Articles

Effect of somatostatin in preventing hyperamylase and post-ERCP pancreatitis

  

  1. 1.Department of General Surgery Endoscopy, Cangzhou Central Hospital, Hebei Province, 
    Cangzhou 061000, China; 2.Department of Pain Management, Cangzhou People′s Hospital, 
    Hebei Province, Cangzhou 061000, China; 3.Department of Traditional Chinese Medicine, 
    Cangzhou Central Hospital, Hebei Province, Cangzhou 061000, China; 4.Department of 
    Neurosurgery, Cangzhou Central Hospital, Hebei Province, Cangzhou 061000, China
  • Online:2020-11-25 Published:2020-11-30

PDF (PC)

70

Abstract: Objective  To investigate the function of somatostatin prophylactic treatment in patients with postoperative hyperamylasemia and post ERCP pancreatitis(PEP) after endoscopic retrograde cholangiopancreatography(ERCP). 
Methods  A total of 280 patients to be treated with ERCP were included and treated with somatostatin 250 μg/h for 24 h. According to no use of somatostatin, they were divided into four groups by random number table 1 h before surgery, immediately after surgery, and 3 h after surgery.Serum amylase levels were detected 5 and 24 hours before and after operation, and the occurrence of postoperative hyperamylase and PEP were observed and compared. 
Results  There was no significant difference in age, sex and operation among the groups. The incidence of postoperative hyperamylasemia in group B, C and D was significantly lower than that in group A(P＜0.05). The incidence of PEP in group B, C and D was significantly lower than that in group A, with statistically significant differences(P＜0.05). Serum amylase levels in group B, C and D were significantly lower than those in group A 5 h and 24 h after surgery(P＜0.05). In addition, there were no significant differences in the incidence of hyperamylasemia, PEP and postoperative blood amylase levels among groups B, C and D(P＞0.05). 
Conclusion  The prophylactic application of somatostatin can reduce the incidence of hyperamylase and PEP after ERCP, and there was no significant difference in the prophylactic effect between preoperative and postoperative administration within 3 h.


Key words: pancreatitis, somatostatin, cholangiopancreatography, endoscopic retrograde